NLRP3, IL-1ß and downstream IL-6 are further activated following cancer therapies including doxorubicin (41–44), tumor cell-targeting CAR T cells (45, 46) and immune checkpoint inhibitors (47, 48), contributing to the cytokine release syndrome and cardiac toxicity. This evidence concerns the gene IL1B and neoplasm.